Are Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Commented Articles
PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.
Read MoreAre Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?
Exploring the Potential Link Between COVID-19 and the Surge in Pediatric NAFLD
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease in children, has seen a consistent rise in prevalence in recent years due to its direct link with obesity and type 2 diabetes (T2D).
“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Understanding Nash: Symptoms, Detection, And Treatment
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
PPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways.
Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Ballooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
An exploration of MAFLD’s clinical utility
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
A brief introduction to the most promising pharmacological agents for NASH
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Lifestyle interventions in NAFLD: what does the evidence say?
Despite an estimated global prevalence of 38%, no pharmacotherapy has yet been approved for non-alcoholic fatty liver disease (NAFLD).
NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
NAFLD and New-Onset Heart Failure: What is the Link?
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.